Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study

Nivolumab for the treatment of urothelial cancers

(2018) Min Yuen Teo et al.   Expert Review of Anticancer Therapy

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial

(2018) Manish R Patel et al.   LANCET ONCOLOGY

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma

(2018) Izak Faiena et al.   Drug Design Development and Therapy

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

(2017) Arjun V Balar et al.   LANCET

Post-treatment prognostic model for patients (pts) with metastatic urothelial cancer (UC) treated with first-line chemotherapy.

(2017) Matt D. Galsky et al.   JOURNAL OF CLINICAL ONCOLOGY

Global cancer statistics, 2012

(2015) Lindsey A. Torre et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Randomized Phase III Study Comparing Paclitaxel/Cisplatin/ Gemcitabine and Gemcitabine/Cisplatin in Patients With Locally Advanced or Metastatic Urothelial Cancer Without Prior Systemic Therapy: EORTC Intergroup Study 30987

(2012) Joaquim Bellmunt et al.   JOURNAL OF CLINICAL ONCOLOGY

First- and second-line therapy for metastatic urothelial carcinoma of the bladder

(2011) F. A. Yafi et al.   Current Oncology